Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Medical Data Vision Co's annualized net income for the quarter that ended in Dec. 2025 was 円581 Mil. Medical Data Vision Co's average shareholder tangible equity for the quarter that ended in Dec. 2025 was 円2,898 Mil. Therefore, Medical Data Vision Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 20.04%.
The historical rank and industry rank for Medical Data Vision Co's Return-on-Tangible-Equity or its related term are showing as below:
TSE:3902'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -21.99 Med: 15.07 Max: 28.15
Current: 9.52
During the past 13 years, Medical Data Vision Co's highest Return-on-Tangible-Equity was 28.15%. The lowest was -21.99%. And the median was 15.07%.
TSE:3902's Return-on-Tangible-Equity is not ranked
in the Healthcare Providers & Services industry.
Industry Median: 10.65
vs TSE:3902: 9.52
Medical Data Vision Co (TSE:3902) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Medical Data Vision Co Return-on-Tangible-Equity Related Terms
Medical Data Vision Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Medical Data Vision Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medical Data Vision Co Return-on-Tangible-Equity Chart
TSE:3902 vs VEEV, TEM, BTSG: Return-on-Tangible-Equity Comparison
For the Health Information Services subindustry, Medical Data Vision Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medical Data Vision Co Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Medical Data Vision Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Medical Data Vision Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 20.04% mean?
Medical Data Vision Co (TSE:3902) has a Return-on-Tangible-Equity of 20.04% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Medical Data Vision Co and its competitors. This is 33% above median its historical median of 15.07.
Is Medical Data Vision Co's Return-on-Tangible-Equity too high?
Medical Data Vision Co's current Return-on-Tangible-Equity of 20.04% is 33% above median its 10-year median of 15.07. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.65. Medical Data Vision Co's value of 20.04% is 88.2% above this industry median. Overall, Medical Data Vision Co has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does Medical Data Vision Co's Return-on-Tangible-Equity compare to VEEV and TEM?
Medical Data Vision Co's Return-on-Tangible-Equity of 20.04% can be compared against companies in the Healthcare Providers & Services industry. The industry median Return-on-Tangible-Equity is 10.65. Medical Data Vision Co's value of 20.04% is 88.2% above this benchmark. While the company's 10-year median is 15.07 vs. the industry median of 10.65, Medical Data Vision Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.65, based on 577 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medical Data Vision Co's current Return-on-Tangible-Equity of 20.04% is 88.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Medical Data Vision Co and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medical Data Vision Co's current Return-on-Tangible-Equity is 20.04%, which is 33% above median its own 10-year median of 15.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medical Data Vision Co stock overvalued right now?
Medical Data Vision Co (TSE:3902) has a current Return-on-Tangible-Equity of 20.04%. The stock's GF Value™ is 円657.61, compared to a current price of 円1,684.00 — trading 156.1% above its estimated fair value. The current Return-on-Tangible-Equity is 20.04%, which is 33% above median its 10-year median of 15.07 and 88.2% above the Healthcare Providers & Services industry median of 10.65. Medical Data Vision Co's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Medical Data Vision Co (TSE:3902), the current Return-on-Tangible-Equity is 20.04% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medical Data Vision Co (TSE:3902) Overvalued in 2026?
Based on GuruFocus' analysis, Medical Data Vision Co stock appears to be overvalued.
The current stock price of 円1,684.00 is trading 156.1% above its estimated GF Value™ of 円657.61.
Key valuation signals for TSE:3902:
Return-on-Tangible-Equity: 20.04% (33% above median its 10-year median of 15.07)
GF Value™: 円657.61 vs. price of 円1,684.00 (156.1% above fair value)
Industry Position: 88.2% above the Healthcare Providers & Services median
No single metric tells the full story. See the TSE:3902 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medical Data Vision Co Ltd provides health information services. The company is engaged in Development, production, sales, Maintenance work of medical information integration system, Analysis, survey and consulting of various medical data, Planning, design, development, and operation of the portal site. Its products include Calteco that allows patients to store and view a part of clinical information themselves and CADA payment service such as medical expenses postpay service that patients can freely set payment terms. Medical Code is a system that utilizes standard format data such as hospitalized outpatient EF and electronic reception data in DPC format to support solving various management problems and other related products.
56GF Score
Get the complete analysis for TSE:3902
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3902 has been successfully added to your 
